Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab

Next Previous
X
Search
Trial Profile

D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Dasatinib (Primary) ; Dexamethasone; Levetiracetam; Prednisone
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms D-ALBA; LAL 2116

    • Most Recent Events

    • 12 Dec 2023 final long-term results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results of a multilevel propensity score weighting analysis comparing rates of hematologic CR in four trials: LAL0904, LAL1205, LAL1509 and LAL2116 presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 Results deriving samples from this study evaluating whether digital droplet PCR (ddPCR) is at least as sensitive as Sanger sequencing (SS) for the detection of the T315Imutation, and if the ddPCR can detect the mutation also at very low levels of minimal residual disease (MRD),ultimately anticipating molecular relapse, presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top